Logo

American Heart Association

  2
  0


Final ID: 4144372

TET2-mutant Clonal Hematopoiesis Promotes Heart Failure with Preserved Ejection Fraction

Abstract Body (Do not enter title and authors here): Introduction: Aging and inflammation are both important risk factors of heart failure with preserved ejection fraction (HFpEF). However, a potential mechanistic link between them in HFpEF pathogenesis remains unknown. Clonal hematopoiesis of indeterminate potential (CHIP) is a common age-related condition characterized by the clonal expansion of hematopoietic stem cell (HSCs) bearing mutations in certain driver genes and is associated with increased inflammation and elevated risk of cardiovascular diseases. However, our understanding of the role of CHIP in HFpEF remains limited.
Methods and Results: We evaluated the prevalence and clinical impact of CHIP in two independent and well-annotated HFpEF cohorts. We compared a single-center registry of deeply phenotyped HFpEF cases at UT Southwestern with age- and sex-matched controls from the Dallas Heart Study (N=108 each), observing that the prevalence of CHIP was significantly higher in HFpEF patients as compared to matched controls (25% vs 19%). We also discovered that TET2 is the most frequently mutated gene in this population (63% in HFpEF vs 40% in controls), while DNMT3A mutations were underrepresented (30% vs 45%). We validated these findings in an external cohort of HFpEF patients from the TOPCAT trial (N=213). Importantly, we discovered that the presence of CHIP is independently associated increased risk of heart failure hospitalization and all-cause mortality (adjusted HR 2.07, 95% CI: 1.01-4.22, p = 0.046).
To determine whether CHIP causally links with HFpEF, mice received Tet2 knockout (KO) vs wildtype bone marrow, and were subjected to a well-established “two-hit” HFpEF induction model. Despite similar systemic responses, the Tet2 KO group manifested exacerbated diastolic dysfunction. This effect is Tet2 specific, as mice harboring HSCs loss of Dnmt3a did not develop such phenotype. Bulk and single-cell RNASeq analyses revealed that HFpEF induction led to an expansion of pro-inflammatory and pro-fibrotic macrophage subsets in the heart, which was exacerbated by CHIP. There is an enrichment of NLRP3/ IL1b inflammatory genes in the Tet2 KO group, and NLRP3 deficiency in HSCs attenuates the phenotype of Tet2 KO-associated HFpEF.
Conclusion: Our results reveal that TET2-mediated CHIP is highly prevalent in HFpEF patients and directly promotes HFpEF pathogenesis. CHIP status could serve as a marker for risk stratification and targeted anti-inflammatory therapies in patients with HFpEF.
  • Pandey, Ambarish  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Hu, Wenhuo  ( St. Jude Children's Hospital , Memphis , Tennessee , United States )
  • Son, Albert  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Young, Kira  ( The Jackson Laboratory , Bar Harbor , Maine , United States )
  • Trowbridge, Jennifer  ( The Jackson Laboratory , Bar Harbor , Maine , United States )
  • Carlsgaard, Peter  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Premnath, Naveen  ( University of Minnesota , Minneapolis , Minnesota , United States )
  • Jiang, Nan  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Daou, Daniel  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Ware, Sarah  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Chung, Stephen  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Thomas, Toby  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Tong, Dan  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Ji, Yuanyuan  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Kroger, Benjamin  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Irion, Camila  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Kalkan, Fatma  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Segar, Matthew  ( Texas Heart Institute , Houston , Texas , United States )
  • Subramanian, Vinayak  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Bayes-genis, Antoni  ( HUGTiP , Badalona , Spain )
  • Author Disclosures:
    Ambarish Pandey: DO have relevant financial relationships ; Consultant:Tricog:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Consultant:Edwards Lifesciences:Active (exists now) ; Consultant:Semler:Active (exists now) ; Consultant:Science37:Active (exists now) ; Research Funding (PI or named investigator):SCPharma:Active (exists now) ; Advisor:Medtronic:Active (exists now) ; Advisor:Axon:Active (exists now) ; Advisor:Bayer:Active (exists now) ; Research Funding (PI or named investigator):Ultromics:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Roche:Active (exists now) | Wenhuo Hu: No Answer | Albert Son: No Answer | Kira Young: No Answer | Jennifer Trowbridge: DO have relevant financial relationships ; Royalties/Patent Beneficiary:Fate Therapeutics:Past (completed) ; Research Funding (PI or named investigator):H3 Biomedicine:Past (completed) | Peter Carlsgaard: No Answer | Naveen Premnath: DO NOT have relevant financial relationships | Nan Jiang: DO NOT have relevant financial relationships | Daniel Daou: DO NOT have relevant financial relationships | Sarah Ware: DO NOT have relevant financial relationships | Stephen Chung: No Answer | Toby Thomas: No Answer | Dan Tong: DO NOT have relevant financial relationships | yuanyuan ji: No Answer | Benjamin Kroger: DO NOT have relevant financial relationships | Camila Irion: No Answer | Fatma Kalkan: No Answer | Matthew Segar: No Answer | Vinayak Subramanian: DO NOT have relevant financial relationships | Antoni Bayes-Genis: DO have relevant financial relationships ; Consultant:Abbott:Past (completed) ; Speaker:Vifor:Past (completed) ; Advisor:Novartis:Past (completed) ; Advisor:Bayer:Active (exists now) ; Advisor:Medtrinic:Active (exists now) ; Consultant:Roche Diagnostics:Active (exists now) ; Advisor:Boehringer Ingelheim:Past (completed) ; Advisor:AstraZeneca:Past (completed) ; Speaker:Abbott:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

From Bench to Bedside in Heart Failure

Monday, 11/18/2024 , 08:00AM - 09:15AM

Abstract Oral Session

More abstracts on this topic:
A20 in the Kidney Epithelium Attenuates Angiotensin II-induced Hypertension by Constraining Renal Tubular NHE3 Expression

Lu Xiaohan, Ren Jiafa, Wen Yi, Griffiths Robert, Yang Ting, Hammer Gianna, Zhuo Jia, Crowley Steven

Cardiac Adaptations and Mitochondrial Protection Through Long Noncoding RNA Regulation in Mice and Human Cardiomyocytes Under Ketotic Conditions

Tran Talan, Katragadda Sai Chandra, Almalki Bandar, Murray James, Gill Navdeep, Albensi Benedict, Speth Robert, Robison Lisa, Gurusamy Narasimman

More abstracts from these authors:
Clinical and Hemodynamic Correlates of Supranormal Ejection Fraction in Heart Failure with Preserved Ejection Fraction (HFpEF)

Dhruve Ritika, Koshy Thomas, Pandey Ambarish, Patel Lajjaben, Subramanian Vinayak, Segar Matthew, Miller James, Lokesh Nidhish, Keshvani Neil, Tong Dan, Chandra Alvin

Natriuretic Peptide Normative Levels and Deficiency Among South Asian Older Adults: The Longitudinal Ageing Study in India

Singh Sumitabh, Singhal Sunny, Segar Matthew, Keshvani Neil, Dey Sharmishtha, Dey Aparajit, Pandey Ambarish

You have to be authorized to contact abstract author. Please, Login
Not Available